ACCP

ACCP = American College of Chest Physicians

Seventh ACCP Consensus Conference on Antithrombotic Therapy

The absorption of dipyridamole from conventional formulations is quite variable and may result in low systemic bioavailability of the drug. A modified-release (extended-release) formulation of dipyridamole with improved bioavailability has been developed in association with low-dose ASA.
Dipyridamole is a pyrimidopyrimidine derivative with vasodilator and antiplatelet properties. Dipyridamole is eliminated mainly by biliary excretion as a glucuronide conjugate and is subject to enterohepatic recirculation. A terminal half-life of 10 h has been reported. This is consistent with the twice-daily regimen used in recent clinical studies.